Akums Drugs and Pharmaceuticals credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
73.073.013.7
−1,608−1,608−563
0.02×0.02×0.00×
−0.48×−0.48×−0.18×
0.14×0.14×0.03×
−2.83×−3.08×−1.21×
3.91×3.91×8.99×
2.1%2.1%0.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,346 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt13.773.073.0
Net Debt-562.8-1,607.6-1,607.6
Total Debt/Equity0.000.020.02
Net Debt/Equity-0.18-0.48-0.48
Total Debt/EBITDA0.030.140.14
Net Debt/EBITDA-1.21-3.08-2.83
Interest Coverage (EBIT/Interest)8.993.913.91
Total Debt/Total Capital %0.442.142.14
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.